Anders Wittrup
Overview
Explore the profile of Anders Wittrup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hedlund H, Du Rietz H, Johansson J, Eriksson H, Zedan W, Huang L, et al.
Nat Commun
. 2023 Feb;
14(1):1075.
PMID: 36841822
Endosomal escape and subsequent cytosolic delivery of small interfering RNA (siRNA) therapeutics is believed to be highly inefficient. Since it has not been possible to quantify cytosolic amounts of delivered...
2.
Adrian G, Konradsson E, Beyer S, Wittrup A, Butterworth K, McMahon S, et al.
Front Oncol
. 2021 Aug;
11:686142.
PMID: 34395253
Background: Irradiation with ultra-high dose rate (FLASH) has been shown to spare normal tissue without hampering tumor control in several studies. Few cell lines have been investigated , and previous...
3.
Sartor H, Minarik D, Enqvist O, Ulen J, Wittrup A, Bjurberg M, et al.
Clin Transl Radiat Oncol
. 2020 Oct;
25:37-45.
PMID: 33005756
Background: It is time-consuming for oncologists to delineate volumes for radiotherapy treatment in computer tomography (CT) images. Automatic delineation based on image processing exists, but with varied accuracy and moderate...
4.
Du Rietz H, Hedlund H, Wilhelmson S, Nordenfelt P, Wittrup A
Nat Commun
. 2020 Apr;
11(1):1809.
PMID: 32286269
Small interfering RNAs (siRNAs) are a new class of promising therapeutic molecules that can be used for sequence-specific downregulation of disease-causing genes. However, endosomal entrapment of siRNA is a key...
5.
Wittrup A, Lieberman J
Nat Rev Genet
. 2015 Aug;
16(9):543-52.
PMID: 26281785
Small interfering RNAs (siRNAs), which downregulate gene expression guided by sequence complementarity, can be used therapeutically to block the synthesis of disease-causing proteins. The main obstacle to siRNA drugs -...
6.
Gilboa-Geffen A, Hamar P, Le M, Wheeler L, Trifonova R, Petrocca F, et al.
Mol Cancer Ther
. 2015 Aug;
14(10):2279-91.
PMID: 26264278
Effective therapeutic strategies for in vivo siRNA delivery to knockdown genes in cells outside the liver are needed to harness RNA interference for treating cancer. EpCAM is a tumor-associated antigen...
7.
Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, et al.
Nat Biotechnol
. 2015 Jul;
33(8):870-6.
PMID: 26192320
A central hurdle in developing small interfering RNAs (siRNAs) as therapeutics is the inefficiency of their delivery across the plasma and endosomal membranes to the cytosol, where they interact with...
8.
Svensson K, Christianson H, Wittrup A, Bourseau-Guilmain E, Lindqvist E, Svensson L, et al.
J Biol Chem
. 2013 May;
288(24):17713-24.
PMID: 23653359
The role of exosomes in cancer can be inferred from the observation that they transfer tumor cell derived genetic material and signaling proteins, resulting in e.g. increased tumor angiogenesis and...
9.
Wittrup A, Zhang S, Belting M
Methods Mol Biol
. 2010 Nov;
683:99-115.
PMID: 21053125
Cell-penetrating peptides (CPPs) are widely used to deliver macromolecular cargoes to intracellular sites of action. Many CPPs have been demonstrated to rely on cell surface heparan sulfate proteoglycans (HSPGs) for...
10.
Wittrup A, Zhang S, Svensson K, Kucharzewska P, Johansson M, Morgelin M, et al.
Proc Natl Acad Sci U S A
. 2010 Jul;
107(30):13342-7.
PMID: 20624969
An increased understanding of cellular uptake mechanisms of macromolecules remains an important challenge in cell biology with implications for viral infection and macromolecular drug delivery. Here, we report a strategy...